Once-a-day pill for stubborn cancer delivers a 62.5% positive response
In what has already been tagged as a “game-changer” for cancer treatment, the potent once-a-day tablet known as divarasib has continued to impress at Phase 1b trial stage, outperforming not just current therapies but its previous trial results.Continue… Continue reading Once-a-day pill for stubborn cancer delivers a 62.5% positive response